Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT). (May 2019)

• Record Type: Journal Article
• Authors: Pathak, Rima S.; Pantarotto, Jason R.; Cook, Graham; Holmes, Oliver; Cross, Peter; MacRae, Robert M.
• Is Part Of: Clinical and translational radiation oncology. Volume 16(2019)
• Page Start: 28
• Page End: 33
• Publication Date: 2019-05
• Subjects: Cancer -- Radiotherapy -- Periodicals; Oncology -- Periodicals; Cancer -- Radiotherapy; Oncology; Radiation Oncology; Neoplasms -- radiotherapy; Translational Medical Research; Periodicals; Electronic journals; Periodicals; 616.9940642
• DOI: 10.1016/j.ctro.2019.01.003
• Languages: English
• ISSNs: 2405-6308

Abstract

Highlights: This study reports on the prognostic ability of haematological parameters for the largest known biopsy-proven stage-I medically inoperable cohort treated with SBRT. After SBRT, the median values of Hb, ALC, ANC and TPC declined whereas the NLR and the PLR increased as compared to pre-SBRT. Anemia along with other parameters was found to be a poor prognostic factor for local control despite treatment with SBRT to doses of >100 Gy BED10 . Simple and minimally invasive methods like a peripheral blood sample can provide prognostic information even for stage-I NSCLC patients. Patient, tumor and treatment factors along with molecular markers should be used to create risk stratification models that can guide therapy.